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Abstract
MicroRNAs (miRNA) are small noncoding,
single-stranded RNAs that inhibit gene expression at a
posttranscriptional level, whose abnormal expression
has been described in different tumors. The aim of our
study was to identify miRNAs potentially implicated
in chronic myeloid leukemia (CML). We detected an
abnormal miRNA expression profile in mononuclear and
CD34+ cells from patients with CML compared with
healthy controls. Of 157 miRNAs tested, hsa-miR-10a,
hsa-miR-150 , and hsa-miR-151 were down-regulated,
whereas hsa-miR-96 was up-regulated in CML cells.
Down-regulation of hsa-miR-10a was not dependent
on BCR-ABL1 activity and contributed to the increased
cell growth of CML cells. We identified the upstream
stimulatory factor 2 (USF2) as a potential target of
hsa-miR-10a and showed that overexpression of USF2
also increases cell growth. The clinical relevance of
these findings was shown in a group of 85 newly
diagnosed patients with CML in which expression of
hsa-miR-10a was down-regulated in 71% of the patients,
whereas expression of USF2 was up-regulated in 60% of
the CML patients, with overexpression of USF2 being
significantly associated with decreased expression of
hsa-miR-10a (P = 0.004). Our results indicate that
down-regulation of hsa-miR-10a may increase USF2 and
contribute to the increase in cell proliferation of CML
implicating a miRNA in the abnormal behavior of CML.
(Mol Cancer Res 2008;6(12):1830–40)
Introduction
MicroRNAs (miRNAs) are noncoding, single-stranded
RNAs of 21 to 25 nucleotides recently implicated in the
regulation of several biological processes, such as cell cycle,
apoptosis, differentiation, and development or tumorigenesis
(1, 2). miRNAs inhibit the expression of specific genes either by
decreasing mRNA stability or by blocking mRNA translation
(2-5). In silico studies have estimated and annotated more than
450 human miRNAs8 (6, 7), many of them evolutionary
conserved and localized in cancer-associated fragile genome
regions (8). The fact that each miRNA may regulate multiple
targets implies that a third of the protein-coding genes in humans
may be regulated by miRNAs (9).
The first evidence for the involvement of miRNAs in human
cancer was described in chronic lymphocytic leukemia in which
deletion of a chromosomal region (13q14) was associated with
down-regulation of miR-15a in the majority of chronic
lymphocytic leukemia patients (68%; ref. 10). It was later
shown that miR-15a and miR-16-1 negatively regulate
expression of the BCL2 protein at the posttranscriptional level,
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inducing apoptosis in leukemic cells (11). Abnormal expression
of miRNAs has currently been described in numerous solid
tumors, such as lung cancer (12, 13), breast cancer (14),
glioblastoma (15), hepatocellular carcinoma (16), endocrine
pancreatic tumors (17), papillary thyroid carcinoma (18),
testicular germ cell tumors (19), and colorectal cancer
(20, 21), but also in hematologic malignancies, such as chronic
lymphocytic leukemia (22), lymphomas (23), acute promyelo-
cytic leukemia (24), and more recently acute lymphoblastic
leukemia (25).
Chronic myeloid leukemia (CML) represents a remarkably
useful model to study new mechanisms of tumorigenesis due to
the fact that the hallmark of the disease is the presence of the
Philadelphia chromosome that is present in >95% of the patients
and is responsible for the disease (26-30). Information about the
implication of miRNAs in the pathogenesis of CML is limited to
the description of abnormal expression of certain miRNAs
(miR-15a, miR-16, miR-142, miR-155, miR-181, miR-221 , and
let-7a) in the CML cell line K562 (31, 32) and up-regulation of
the polycistronicmiR-17-92 cluster in CML patients (33). Based
on the analysis of the miRNA profile expression in patients with
newly diagnosed CML, we have determined that hsa-miR-10a,
hsa-miR-150 , and hsa-miR-151 are down-regulated, whereas
hsa-miR-96 is up-regulated in CML cells. Down-regulation of
hsa-miR-150 and hsa-miR-151 is mediated by BCR-ABL1
expression, whereas down-regulation of hsa-miR-10a is BCR-
ABL1 independent. In this study, we show that down-regulation
of hsa-miR-10a results in increased expression of the upstream
stimulatory factor 2 transcription factor (USF2), which contrib-
utes to the increased cell growth of CML cells.
Results
A miRNA Expression Pattern Discriminates CML Patients
from Healthy Donor Samples
We analyzed the expression profile of 157 miRNAs by
quantitative real-time PCR (Q-RT-PCR) using Taqman meth-
odology (PE Applied Biosystems) in mononuclear cells (MNC)
and CD34+ cells from patients with CML (n = 6) at diagnoses
and control healthy donors (n = 6). For comparison of miRNA
expression, data on every sample were normalized using the
expression of the housekeeping genes GUSB or U6 as
described (34, 35). Relative quantification and supervised
analysis comparing bone marrow (BM) MNCs of CML patients
identified 53 differentially expressed miRNAs, 23 of them up-
regulated and 30 down-regulated in CML patients with respect
to healthy donors. Cluster unsupervised analysis based on
differentially expressed miRNAs generated a tree that clearly
distinguished between both groups (Fig. 1A). To assess a more
homogeneous population of cells and because CML is a clonal
stem cell disease, we did the same analysis using CD34+ cells
from the same samples. Eleven miRNAs were differentially
expressed, 10 of them down-regulated and 1 up-regulated in
CML patients. Cluster unsupervised analysis based on
differentially expressed miRNAs generated a similar tree
distinguishing CML samples from normal donors (Fig. 1B).
When a further statistical analysis using Statistical Package
for the Social Sciences was done comparing CML and healthy
donor MNCs, only 34 of the 53 differentially expressed
miRNAs maintained their statistically significant differences
(P < 0.05; Supplementary Table S1). The same analysis done
with CD34+ cells from patients and donors confirmed the
differential expression of the 11 miRNAs (Supplementary
Table S2). The results of the analysis were the same whether we
used GUSB or U6 genes for normalization. We also did a
comparison between the miRNA expression profile of CML
MNC and CD34+ cells and healthy donor MNC and CD34+
cells, which showed 61 and 45 miRNAs to be differentially
expressed in CML patients and normal donors, respectively,
between MNC and CD34+ cells (Supplementary Fig. S1).
The analysis of those miRNAs differentially expressed
both in BM MNC and CD34+ cells of CML patients in
comparison with healthy donors showed that six miRNAs were
differentially expressed in both comparisons, five of them
down-regulated (hsa-miR-10a, hsa-miR-125a, hsa-miR-150,
hsa-miR-151 , and hsa-miR-199s ) and one up-regulated
(hsa-miR-96) in CML patients with respect to healthy donor
samples, indicating a higher likelihood of these miRNAs to be
involved in CML pathogenesis. To confirm the results, we
analyzed the expression of five of these six miRNAs (hsa-miR-
10a, hsa-miR-96, hsa-miR-125a, hsa-miR-150 , and hsa-miR-
151) in MNC and CD34+ cells from another 16 newly
diagnosed CML patients and another 6 healthy donors by
Q-RT-PCR using individual Taqman miRNA assays. hsa-miR-
199s miRNA expression was not analyzed because this miRNA
has been eliminated from the miRNA annotation list. The
analysis confirmed the statistically significant differences in the
expression of four of five miRNAs (hsa-miR-10a, hsa-miR-96,
hsa-miR-150 , and hsa-miR-151) between CML and healthy
donors (Table 1), suggesting that these miRNAs could be
directly implicated in the pathogenesis of CML.
Down-Regulation of hsa-miR-10a in CML Is Not Mediated
by BCR-ABL1 Activity
As CML is characterized by the presence of the fusion
protein BCR-ABL1, which shows an increased tyrosine kinase
activity, we reasoned that abnormal expression of hsa-miR-10a,
hsa-miR-150, hsa-miR-151 , and hsa-miR-96 observed in CML
patients could be dependent on BCR-ABL1 or its kinase
activity. To test this hypothesis, we analyzed the expression of
these miRNAs by Q-RT-PCR in the Mo7e and Mo7e-p210 cell
line before and after treatment with imatinib, a specific inhibitor
of BCR-ABL1 kinase activity, for 24 hours (36). Whereas
Mo7e-p210 cells showed a reduced expression of hsa-miR-150
and hsa-miR-151 in comparison with Mo7e cells, treatment
with imatinib induced an up-regulation of expression of both
miRNAs in Mo7e-p210 cells. These results suggest that BCR-
ABL1 kinase activity induces down-regulation of hsa-miR-150
and hsa-miR-151 in CML (Supplementary Fig. S2A and B). No
expression of hsa-miR-96 was detected in any of the cell lines
before or after treatment with imatinib. Whether a genetic
abnormality is responsible for the lack of hsa-miR-96
expression in the parental Mo7e cell line is currently unknown.
Unlike what we observed in patients with CML in which
expression of hsa-miR-10a was significantly down-regulated
in 71% of the patients, the expression of hsa-miR-10a
was increased in Mo7e-p210 and treatment with imatinib had
no statistically significant effect on miRNA expression
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(Supplementary Fig. S2C). Expression of hsa-miR-10a was
also increased in TCC-S cells, whereas BV173 and KU812 cell
lines showed a reduced hsa-miR-10a expression in comparison
with Mo7e (Fig. 2A). Expression of hsa-miR-10a in CML-
derived cell lines was confirmed by Primer extension analysis
(Fig. 2B). Quantification of the primer extension gave a similar
result than the normalization of hsa-miR-10a expression
obtained by Q-RT-PCR, ensuring the reliability of both
techniques (data not shown). Although hsa-miR-10a is down-
regulated in CML cells, which express BCR-ABL1, expression
of hsa-miR-10a in these cells is unlikely to depend on
BCR-ABL1 activity based on the following facts: (a) Mo7e-
p210 does not show a down-regulation of hsa-miR-10a in
comparison with Mo7e, (b) treatment with imatinib does not
significantly affect the expression of hsa-miR-10a , and (c)
CML-derived cell lines show different hsa-miR-10a levels.
Table 1. miRNAs Differentially Expressed in BM MNC and CD34+ Cells between CML Patients and Healthy Donor
miRNA miRNA Sequence Genome Location P value CD34+ CML/HD P value MNCs CML/HD
hsa-miR-10a uacccuguagauccgaauuugug 17q21.32 0.003 0.04
hsa-miR-96 uuuggcacuagcacauuuuugc 7q32.2 0.004 0.127
hsa-miR-125a ucccugagacccuuuaaccuguga 19q13.41 0.955 0.568
hsa-miR-150 ucucccaacccuuguaccagug 19q13.33 0.018 0.003
hsa-miR-151 acuagacugaagcuccuugagg 8q24.3 0.004 0.018
FIGURE 1. Hierarchical cluster analysis of
miRNA expression in CML patients and
healthy donor samples. Cluster analysis of
expression of 157 miRNA using MNC (A) or
CD34+ cells (B) of patients with CML versus
healthy donors. The dendrogram is shown on
the top of the figure. miRNAs differentially
expressed are depicted with the names
included.
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USF2 Is a Potential Target of hsa-miR-10a
As biological significance of miRNA deregulation relies on
their gene targets, we analyzed the predicted targets of hsa-miR-
10a. The analysis was done using four algorithms, mirBase,
miRanda, TargetScan, and PicTar, commonly used to predict
human miRNA gene targets. Because any of the four
approaches generate an unpredictable number of false positives,
results were intersected to identify the genes commonly
predicted by at least three of the algorithms. Results are shown
in Supplementary Table S3.
We next analyzed whether any of the predicted targets of
hsa-miR-10a were up-regulated in CML CD34+ cells. Thus, we
compared the list of putative targets with the list of up-regulated
genes found in gene array studies done comparing the gene
expression profile of CD34+ cells from CML patients at
diagnoses and healthy donor CD34+ cells (37). We found that
the expression of transcription factor USF2 showed an inverse
correlation with the expression of hsa-miR-10a being up-
regulated in CML CD34+ cells (Supplementary Table S4). As
predicted by PicTar,9 there was complementarity between
hsa-miR-10a and USF2 3¶-untranslated region (UTR).
To show whether hsa-miR-10a could regulate the expression
of USF2, RKO cells were transfected with the pre-miR-10a or
anti-miR-10a molecules and the expression of hsa-miR-10a,
HOXA1 , and USF2 mRNA was analyzed by Q-RT-PCR. This
cell line was used for technical reasons, as the colon carcinoma–
derived RKO cell line can be efficiently transfected unlike
leukemia cell lines. Expression ofHOXA1 mRNA, a known hsa-
miR-10a target (38, 39), was used as control. Transfection of
RKO cells with Silencer FAM-labeled negative control showed a
cell viability of 93% and a transfection efficiency of 88% by
fluorescence-activated cell sorting (Supplementary Fig. S3).
Transfection of RKO with anti-miR-10a induced a significant
reduction of hsa-miR-10 expression level and an increase in the
mRNA levels of HOXA1 and USF2 in comparison with cells
transfected with the anti-miR scrambled control or negative
control (Supplementary Fig. S4). In contrast, a significant
increase of hsa-miR-10 expression level and a decrease of
mRNA levels of HOXA1 and USF2 were found in RKO cells
transfected with pre-miR-10 (Supplementary Fig. S4).
To further show the role of hsa-miR-10 in CML,
nucleofection of the CML-derived KU812 cell line (viability
was 78% and transfection efficiency was 96% by fluorescence-
activated cell sorting using BLOCK-iT Fluorescent Oligo;
Supplementary Fig. S5) was done. KU812 cells were chosen as
they show low levels of hsa-miR-10 , similar to what was
observed in CML cells from patients (Fig. 2A). Transfection
with anti-miR-10a induced a decrease in the expression of hsa-
miR-10 , which was smaller than the one observed in RKO cells,
but a higher increase in the levels of HOXA1 and USF2 mRNA.
Similarly, KU812 cells nucleofected with pre-miR-10 showed
an increase in expression of hsa-miR-10a and a decrease in
HOXA1 mRNA and USF2 mRNA and protein levels (Fig. 3A
and B). These data indicate that hsa-miR-10a regulates the
expression of USF2 (at least) through decrease in mRNA
stability. In addition, we analyzed the expression of other genes
presumably not regulated by hsa-miR-10a , such as GAPDH,
RPS18 , and CCND1 , and found them not to be regulated by
this miRNA (Supplementary Fig. S6).
To evaluate whether USF2 is a potential target of hsa-miR-
10a , we did a Renilla luciferase reporter assay with a vector
containing the putative USF2 3¶-UTR target site downstream
of a Renilla reporter gene (Renilla-USF2 3¶-UTR vector).
Predicted base pairing between hsa-miR-10a and a putative
target site in the 3¶-UTR of USF2 shows perfect complemen-
tarity between nucleotides 2 to 8 of hsa-miR-10a and the target,
resulting in a seed of seven nucleotides (Fig. 4A). Renilla-
USF2 3¶-UTR vector, control vector containing firefly lucifer-
ase, and pre-miR-10a or negative precursor-miR control were
transfected into RKO cell line. Firefly luciferase activity was
evaluated to normalize for transfection efficiency. Renilla
luciferase activity of RKO cells transfected with pre-miR-10a
was significantly lower (P = 0.001) than RKO cells transfected
with negative precursor-miR control (Fig. 4B). These data
indicate that USF2 is a potential target of hsa-miR-10a .
USF2 Is Up-Regulated in CML Patients
To confirm our results in a more clinically relevant model, we
analyzed the expression of USF2 in BM MNCs from a group of
patients with newly diagnosed CML (n = 85) and in healthy
donors (n = 21). Normalized ratios for USF2 expression
determined in BM specimens, from healthy individuals
FIGURE 2. Expression analysis of hsa-miR-10a in CML-derived cell
lines. A. hsa-miR-10a expression was analyzed in Mo7e, Mo7e-p210,
TCC-S, KU812, and BV173 cell lines by Q-RT-PCR. Expression of
miRNAs was normalized and expressed as a ratio of Mo7e expression.
Columns, mean of three different experiments; bars, SD. B. hsa-miR-10a
expression analysis by primer extension in Mo7e, Mo7e-p210, TCC-S,
KU812, and BV173 cell lines. Negative, buffer/oligonucleotide sample. U6
oligonucleotide was used as a loading control.
9 http://pictar.bio.nyu.edu
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(NUSF2 ratios) fell between 82% and 100% (mean NUSF2: 94 F
7%). However, CML patient mean NUSF2 was 225 F 205%
(range, 89-1,057%), significantly higher than ratios found in
healthy donors (P = 0.01). Moreover, a NUSF2 value above
125% (determined as the mean from healthy donors plus 3 SD)
was chosen to define overexpression of USF2 in CML samples.
Using this cutoff value, up-regulation of USF2 was found in
60% (51 of 85) of CML patients.
We also analyzed hsa-miR-10a expression in the same group
of CML patients. Mean expression of hsa-miR-10a was 37%
(range, 0.05-6,690%) being down-regulated in 60 of 85 (71%)
CML patients (down-regulation was considered when expres-
sion of hsa-miR-10a was lower than the mean  4 SD)
compared with normal BM cells. CML patients with a decreased
expression of hsa-miR-10a miRNA showed overexpression of
USF2 mRNA, whereas CML patients with normal levels of
hsa-miR-10a presented normal USF2 mRNA expression
(hsa-miR-10a expression was 85 F 159% in CML patients
with up-regulation of USF2 , and 515F 1,210% in patients with
normal USF2 expression; P = 0.004). These results lead us to
suggest that hsa-miR-10a down-regulation may cause increased
levels of USF2 also in CML cells from patients.
Down-Regulation of hsa-miR-10a and Overexpression of
USF2 Increase CML Cell Growth
We wanted to study whether down-regulation of hsa-
miR-10a or up-regulation of USF2 could lead to increased cell
growth of CML cells and, therefore, could be involved in the
development or progression of CML. To evaluate this, hsa-
miR-10a expression levels were altered in KU812 cells by
nucleofection with pre-miR-10a or anti-miR-10 and cell growth
was evaluated and compared with that of cells transfected with
the pre-miR or anti-miR scrambled controls, respectively.
Interestingly, an increase in hsa-miR-10a expression (Fig. 5A),
which was associated with a decrease in USF2 protein expression
(Fig. 5B), induced a decrease in cell growth (Fig. 5C), whereas
a decrease in hsa-miR-10a expression resulted in an increase
in cell growth (Fig. 5D).
Finally, to examine whether USF2 expression could
participate in hsa-miR-10a –mediated regulation of cell growth,
small interfering RNAs (siRNA) against USF2, or siRNA
Silencer Negative Control-1, were nucleofected in KU812 cells.
siRNAs against USF2 efficiently decrease USF2 expression as
detected by Q-RT-PCR (Fig. 6A) or by Western blot analysis
(Fig. 6B). Down-regulation of USF2 with siRNAs resulted in a
decrease in cell growth compared with control cells (Fig. 6C
and D). These results indicate that down-regulation of hsa-miR-
10a and consequently overexpression of USF2 participate in
the abnormal growth of CML cells.
Discussion
Treatment of CML has notably been improved by the
development of imatinib mesylate, a tyrosine kinase inhibitor
that blocks the kinase activity of BCR-ABL1, defining this
drug as the gold standard first-line therapy for CML patients
(36, 40, 41). In contrast, it has been recently shown that
imatinib mesylate does not inactivate all BCR-ABL1–activated
signaling pathways that are essential for CML cell survival
FIGURE 3. Quantitative
expression of hsa-miR-10a,
HOXA1 , and USF2 mRNA
levels in KU812 cells. A.
KU812 cells were transfected
by nucleofection with pre-
miR-10a, scrambled precur-
sor control, anti-miR-10a,
and scrambled anti-miR con-
trol as described in Materials
and Methods. Cells were har-
vested 48 h after transfection,
and hsa-miR-10a, HOXA1 ,
and USF2 expression was
analyzed by Q-RT-PCR.
HOXA1 and USF2 levels in-
creased in cells nucleofected
with anti-miR-10a and de-
creased in cells nucleofected
with pre-miR-10a. Columns,
mean of three different experi-
ments; bars, SD. B. Western
blot analysis of USF2 protein
expression 48 h after trans-
fection with the pre-miR-10a
or scrambled precursor con-
trol. h-Actin was used as a
loading control.
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(42). This implies that persistent malignant progenitors can be a
potential source of relapse in CML patients and that there is a
need to improve our understanding of the biology of CML to
provide new targets for therapy. The recent implication of
miRNAs in the regulation of important biological processes
altered in CML, such as cell cycle, apoptosis, and adhesion (2),
establishes these small RNA molecules as potential players in
CML pathogenesis.
The result of the current study identifies certain miRNAs
(hsa-miR-10a, hsa-miR-96, hsa-miR-150 , and hsa-miR-151) to
be abnormally regulated in patients with CML and thus
provides support to our hypothesis that miRNAs could be
implicated in CML. While this article was in preparation,
another study described the up-regulation of the polycistronic
miR-17-92 cluster in CD34+ cells of CML patients (33). Unlike
that study, we did not observe an up-regulation of miR-17-92 in
CML CD34+ cells. The different results could be explained on
the bases of the different strategies used for normalization.
Whereas normalization of miRNA expression was done using
the expression of hsa-miR-16 miRNA in the study from
Venturini et al. (33), we used expression of GUSB and U6
genes for normalization as this strategy has been validated in
recent studies (34). It is important to point out that the analysis
of differentially expressed miRNAs in CD34+ cells of CML
patients indicates that hsa-miR-16 is down-regulated, thus
making this miRNA inappropriate for normalization of data.
Furthermore, hsa-miR-16 negatively regulates the antiapoptotic
protein BCL2 (11) that has also been implicated in CML (43).
The use of a certain miRNA for normalization of the data based
on the assumption that expression of the specific miRNAs is
constant regardless of the tissue or the disease may not be a
reliable way of normalizing the results (10, 12, 21, 44).
As we and others have previously shown, the presence of the
p210 BCR-ABL1 fusion oncoprotein regulates directly or
indirectly the mRNA and/or the protein expression of several
genes that participate in the deregulation of the cell cycle,
apoptosis, and adhesion observed in CML cells (45, 46). We
decided to examine whether the abnormal expression of hsa-
miR-10a, hsa-miR-96, hsa-miR-150 , and hsa-miR-151 could be
dependent of BCR-ABL1 and its kinase activity. The result
showed that hsa-miR-150 and hsa-miR-151 decreased as a
result of functional expression of BCR-ABL1. Further
studies are required to address the molecular mechanism of
BCR-ABL1–mediated down-regulation and whether down-
regulation of hsa-miR-150 and hsa-miR-151 is essential for
BCR-ABL1 role in CML.
The expression of hsa-miR-10a was independent of BCR-
ABL1 activity and this could in fact suggest that abnormal
expression of hsa-miR-10a is associated with the development
of the disease. Interestingly, in a recent study in hematopoietic
CD34+ cells, hsa-miR-10 has been designated as one of the 33
miRNAs implicated in hematopoiesis (hematopoietic-expressed
miRNAs; ref. 47). According to this model, expression of
these miRNAs would be responsible for controlling differenti-
ation of hematopoietic cells so that once differentiation is
activated certain miRNAs are down-regulated. Consistent with
Georgantas et al. (47), hsa-miR-10a was normally expressed in
BM MNC and CD34+ cells of healthy donor samples, but the
expression of this miRNA was down-regulated in CML patient
samples. Furthermore, reexpression of hsa-miR-10a in CML
cells decreased cell growth, thus supporting the potential role of
hsa-miR-10a in CML disease.
Different mechanisms, such as (22) localization of miRNA
in a loss of heterozygosity region (8), epigenetic methylation of
the CpG islands of miRNAs (48, 49), mutations in miRNA
sequences (22), or altered miRNA maturation or stability (50),
could be implicated in the regulation of miRNA expression.
hsa-miR-10a is localized in 17q21.32 genome region, which is
not a chromosome fragile site or a commonly deleted
chromosome region in CML. Furthermore, a defined CpG
island could not be found near the hsa-miR-10a chromosome
localization, making unlikely that an epigenetic methylation
mechanism participates in the regulation of hsa-miR-10a in
CML. In addition, we did not detect an up-regulation of
hsa-miR-10a expression after treatment of KU812 cells with
the inhibitor of histone deacetylase trichostatin A or the
demethylating agent 5-aza-2¶deoxycytidine (data not shown),
further indicating that hsa-miR-10a expression is not regulated
by abnormal methylation or histone acetylation.
Down-regulation of hsa-miR-10a in CML could not be
explained by the presence of gene mutations, as we did not find
FIGURE 4. USF2 is a target of hsa-miR-10a . A. Complementarity
between hsa-miR-10a and the USF2 3¶-UTR as predicted by PicTar. B.
Renilla luciferase reporter assay of RKO cell line transfected with Renilla -
USF2 vector, control vector containing luciferase, and pre-miR-10a or
negative precursor-miR control. Columns, mean of three experiments from
three independent transfections; bars, SD.
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any point mutations in the 201-bp genomic region that includes
the hsa-miR-10a sequence using any of the studied samples of
CML CD34+ (data not shown). We also compared the
expression of DROSHA and DICER genes, components of
the miRNA maturation machinery, by Q-RT-PCR in 16 BM
samples of Philadelphia chromosome–positive, chronic-phase
CML patients and 10 healthy donors to determine whether the
maturation of miRNA could be responsible for the abnormal
expression of hsa-miR-10a . No statistically significant differ-
ences in the expression of DROSHA or DICER were found
between CML and healthy donors, suggesting that alterations in
the processing machinery of miRNAs are not responsible for
the decreased expression of hsa-miR-10a in CML (data not
shown). We also believe that hsa-miR-10a should be properly
matured in CML cells as we failed to detect accumulation of
hsa-miR-10a pre-miRNA or pri-miRNA precursors by primer
extension (data not shown). Further studies will be required to
identify the mechanisms that regulate the hsa-miR-10a
expression in CML.
In conclusion, our study shows that the expression of the
hsa-miR-10a miRNA is down-regulated in CML patients and
that hsa-miR-10a regulates expression of USF2 . Further, these
abnormalities are independent of the BCR-ABL1 activity and
are implicated in the abnormal growth of CML cells. Further
studies will be necessary to identify other hsa-miR-10a targets
and to show the exact role of hsa-miR-10a and its target genes
in the development of CML.
Materials and Methods
Cell Lines and Patient Samples
Human-derived Mo7e, Mo7e transfected with p210 isoform
of BCR-ABL1 (Mo7e-p210), and CML-derived cell lines
TCC-S, KU812, and BV173 were grown in RPMI 1640
supplemented with 20% fetal bovine serum, 20 mmol/L HEPES
buffer, and penicillin-streptomycin (all of them from BioWhit-
taker) with (Mo7e) or without (Mo7e-p210, TCC-S, KU812,
and BV173) 10 Ag/AL of recombinant human interleukin-3
(PeproTech) as described (45, 46). In some experiments, Mo7e-
p210 cells were treated with 2 Amol/L imatinib for 24 h.
Colon carcinoma–derived RKO cell line was grown in MEM
(Life Technologies) supplemented with 10% fetal bovine serum
and penicillin-streptomycin (BioWhittaker).
FIGURE 5. hsa-miR-10a transfection decreases growth of CML cells. A. hsa-miR-10a expression analysis by Q-RT-PCR 4 and 6 d after pre-miR-10a
nucleofection. B.Western blot analysis of USF2 protein 4 and 6 d after pre-miR-10a nucleofection. h-Actin was used as a loading control. C and D. KU812
cells were transfected by nucleofection with pre-miR-10a molecule and scrambled precursor control (C) and anti-miR-10a and anti-scrambled control (D).
Cell viability and total cell counts were determined at various times by trypan blue exclusion. KU812 N, KU812 scrambled cells; KU812 miR-10a, KU812
transfected with pre-miR-10a molecule. Points, mean of three experiments; bars, SD.
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BM cells were obtained from patients with CML at
diagnosis and from normal volunteer donors. All CML patients
were 100% Philadelphia chromosome positive by conventional
cytogenetic analysis. MNCs were isolated by sedimentation on
Ficoll-Hypaque gradients. CD34+ cells were isolated using the
MACS CD34+ isolation kit (Miltenyi Biotec) and the
AutoMACS selection device as described (45). CD34+ purity
was always above 90%. All studies were approved by the
Investigational Review Boards at the University of Navarra. All
the samples were obtained after informed consent of the
patients and donors.
RNA Extraction and Reverse Transcription
Total RNAwas extracted with Ultraspec (Biotecx) following
the manufacturer’s instructions. Total RNA (5 ng) was used to
synthesize a specific cDNA of each analyzed miRNA according
to the Taqman MicroRNA Assay protocol (PE Applied
Biosystems). Reverse transcriptase reactions contained 1.5 AL
of miRNA-specific stem-loop reverse transcriptase primer and
6 AL of Master Mix composed of 5 ng RNA, 1 reverse
transcriptase buffer, 0.25 mmol/L of each deoxynucleotide
triphosphate, 3.33 units/AL of MultiScribe reverse transcriptase,
and 0.25 unit/AL of RNase inhibitor (PE Applied Biosystems).
The 7.5 AL reactions were incubated in a PE Applied
Biosystems 2720 Thermo Cycler in a 96-well plate for
30 min at 16jC, 30 min at 42jC, and 5 min at 85jC.
Expression Analysis by Q-RT-PCR
Expression of 157 miRNAs was analyzed using specific
primers and Taqman probe for each miRNA according to the
TaqmanMicroRNAAssay protocol. Q-RT-PCRwas done in a PE
Applied Biosystems 7300 Sequence Detection system using
0.7 AL of reverse transcriptase product of each miRNA in a
reaction volume of 10 ALwith 1 Taqman Universal PCRmaster
mix and 1 AL of primer and probe mix according to the Taqman
MicroRNA Assay protocol (PE Applied Biosystems). The
reactions were incubated in a 96-well optical plate at 95jC for
10 min followed by 40 cycles of 95jC for 15 s and 60jC for 10
min. TheC t data were determined using default threshold settings.
Validation of miRNAs was done by Q-RT-PCR using the
standard curve method [User Bulletin Nj2, part number (PN)
4303859; PE Applied Biosystems]. Individual Taqman
miRNA assays for hsa-miR-10a (PN: 4373153), hsa-miR-96
(PN: 4373010), hsa-miR-125a (PN: 4373149), hsa-miR-150
(PN: 4373127), and hsa-miR-151 (PN: 4373179) were used (PE
Applied Biosystems).
Expression of HOXA1 was analyzed using Assay-
on-Demand (Hs 00171793_m1; PE Applied Biosystems).
Q-RT-PCR for USF2, DROSHA , and DICER was done
with the LightCycler technology using 1 AL cDNA in
20 AL reaction volume with 0.4 Am/L of each primer
[USF2 , 5¶-AAAAATTGATGGAACCAGAACACC-3¶ (for-
ward) and 5¶-TCCCGTCTTGCTGTTGTC-3 ¶ (reverse);
DROSHA , 5¶-CAAGATGACCCAACTCCCT-3¶ (forward) and
FIGURE 6. Inhibition of USF2 by siRNA induces a decrease in cell growth. KU812 cells were transfected by nucleofection with USF2 siRNA and Silencer
Negative Control-1.A. USF2 mRNA analysis by Q-RT-PCR.B.Western blot analysis of USF2 protein. h-Actin was used as a loading control.C. Cell viability
and total cell counts of transfected KU812 cells were determined at various times by trypan blue exclusion. D. Expression of USF2 protein by Western blot
analysis at 6 and 8 d after siUSF2 nucleofection. h-Actin was used as a loading control. KU812 N, KU812 scrambled cells. A to C. Values represent mean F
SD of three experiments.
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5¶-TTCTGAACAATGGCAGTCCG-3¶ (reverse); and DICER ,
5¶-TCTGCCAATTAACTCACCTC-3¶ (forward) and 5¶-TAAC-
TATCCCTCAAACACTCTG-3¶ (reverse)] and 2 AL of 10
LightCycler FastStart DNA Master SYBR Green I. The final
Mg2+ concentration in the reaction mixture was adjusted to
3.5 mmol/L. The following program conditions were applied
for Q-RT-PCR running: 95jC for 10 min; amplification
program, consisting of 45 cycles at 95jC for 10 s, 62jC for
10 s, and 72jC for 10 s; melting program, 1 cycle at 95jC for
0 s, 40jC for 60 s, and 90jC for 0 s; and cooling program,
1 cycle at 40jC for 60 s. The temperature transition rate was
20jC/s, except in the melting program, which was 0.2jC/s
between 40jC and 90jC. U6 gene was used as reference
gene. To reduce the variation between different assays and
samples, a procedure based on the relative quantification of
target genes versus their controls/calibrators in relation to the
reference gene was used. Calculations were automatically
done by the LightCycler software (RealQuant, version 1.0,
Roche). The normalized ratios of USF2 (NUSF2), DROSHA
(NDROSHA), and DICER (NDICER) expression were obtained
from the following equation and expressed as percentage of
the control/calibrator:
Normalized ratio ðNÞ
¼ ðEtargetÞCp target ðcontrolsampleÞ = ðErefÞCp ref ðcontrolsampleÞ:
Efficiencies (E) of each gene were calculated from the slopes
of crossover points (Cp) versus DNA concentration plot
according to the formula E = 10(1/slope). DCp corresponded
to the difference between control/calibrator Cp and sample Cp,
either for the target or for the reference sequences. The selected
controls/calibrators were BM specimens from healthy donors.
They were considered as 100% expression.
Primer Extension
hsa-miR-10a expression was analyzed by Primer extension
technique as described previously (51) using (5¶-TACA-
CAAATTCGGATCTACA-3¶) oligonucleotide for hsa-miR-10a
and (5¶-TGCTAATCTTCTCTGTATCGT-3¶) oligonucleotide for
U6 . Six picomoles of g-ATP–labeled hsa-miR-10a oligonucle-
otide were incubated with 3 Ag of total RNA and only 0.25 Ag of
RNAwith oligonucleotide U6 . Samples were loaded onto a 14%
polyacrylamide gel and separated by electrophoresis. Gels were
dried and exposed to a screen that was developed in a Cyclone
phosphorimager (Perkin-Elmer).
Normalization and Data Analysis
Expression of miRNAs was normalized using the expression
of GUSB or U6 genes in each sample as previously described
(34). Primers for expression analysis of GUSB were GUS-R
(5¶-CCGAGTGAAGATCCCCTTTTTA-3¶) for the reverse
transcription and primers GUS-F (5¶-GAAAATATGTGGTTG-
GAGAGCTCATT-3¶), GUS-R, and probe GUS-P (5¶-FAMC-
CCAGCACTCTCGTCGGTGACTGTTCATAMRA-3¶) for the
Q-RT-PCR. For expression of U6 , we used Taqman RNU6B
assay (PN 4373381; PE Applied Biosystems). Relative
quantification of expression of analyzed 157 miRNAs was
calculated with the 2DDC t method (User Bulletin Nj2, PN
4303859; PE Applied Biosystems). The data are shown as DC t
of the relative quantity of target miRNAs, normalized, and
compared with expression in healthy donor samples.
An unsupervised cluster analysis was carried out using
Cluster and TreeView software (52). Hierarchical clustering
based on the average linkage method with the centered
correlation metric was done. To identify genes with statistically
significant changes in expression between both groups, we did
a supervised analysis using the algorithm significant analysis of
microarrays (53). All data were permuted over 100 cycles by
using the two-class (unpaired) format.
Finally, miRNA expression was compared between CML
and healthy donor samples using Statistical Package for the
Social Sciences package, version 13.0 (SPSS). Differences
between two independent groups were analyzed by the
Student’s t test or the Mann-Whitney U test depending on
variable distribution (54). A P value of V0.05 was considered
significant.
Cell Line Transfection
The pre-miR-10a precursor molecule, negative precursor-
miR control, anti-miR-10a inhibitor, negative anti-miR control,
USF2 siRNA (AM16708), and Silencer Negative Control-1
were purchased from Ambion. The colon carcinoma–derived
RKO cell line was transfected with each of the precursor and
inhibitor molecules at final concentration of 50 nmol/L using
Lipofectamine RNAiMAX (Invitrogen Life Technologies)
according to the manufacturer’s instruction. In a different set
of experiments, the CML-derived cell line KU812 was
nucleofected using 100 AL of Cell Line Nucleofector Solution
V (Amaxa GmbH) with each of the precursor-miR, inhibitor-
miR molecules, USF2 siRNA, and Silencer Negative Control-1
at a final concentration of 50 nmol/L using program T-06 from
the Nucleofector device (Amaxa GmbH). After 48 h, cells were
harvested to analyze the expression of hsa-miR-10a, HOXA1 ,
or USF2 by Q-RT-PCR. Transfection efficiency was deter-
mined by flow cytometry using the Silencer FAM-labeled
Negative Control (Ambion) for the RKO cell line and BLOCK-
iT Fluorescent Oligo (Invitrogen Life Technologies) for the
KU812 cell line. Cell viability and total cell counts were
determined at various times by trypan blue exclusion and found
to be always above 80%.
hsa-miR-10a Genomic Sequence Analysis
DNA from CML cells was extracted using QIAamp DNA
Mini kit (Qiagen). PCR for amplification of the 201-bp genomic
sequence where hsa-miR-10a is located was done in a total
volume of 25 AL using 1 AL genomic DNA, 1 unit AmpliTaq
Gold DNA Polymerase (PE Applied Biosystems), 1.5 mmol/L
MgCl2, 0.2 mmol/L deoxynucleotide triphosphates, and
20 pmol of each primer (10a-D: 5¶-CTGGAAAATTTCTGGGC-
CAA-3 ¶ and 10a-R: 5 ¶-CCAGACTGTCCTCATTCA-
GAAAAA-3¶). Amplification products were purified using
QIAquick PCR Purification kit (Qiagen) and sequenced
with ABI PRISM d-Rhodamine Terminator Cycle Sequencing
kit in an ABI PRISM 377 DNA Sequencer (PE Applied
Biosystems).
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Renilla Luciferase Assay
Renilla luciferase construct Renilla-USF2 3¶-UTR was
made by ligating oligonucleotides (USF2-3¶-UTR-D: 5¶-CTA-
GAGCTGCCTCCTGCTCTCTGGAGGTACTGAGA-
CAGGGTGCTGATGGGAAGGAGGAGC-3¶; USF2-3¶-UTR-
R: 5¶-GGCCGCCCTCCTTCCCATCAGCACCCTGTCTCAG-
TACCTCCAGAGAGCAGGAGGCAGCT-3¶) containing the
putative target site of USF2 3¶-UTR into XbaI-NotI site of the
Renilla reporter vector (pRL-SV40, Promega). Cells (250,000)
of RKO cell line were cotransfected using Lipofectamine
(Invitrogen) with 0.5 Ag of Renilla-USF2 3¶-UTR vector, 2 Ag of
the control vector containing firefly luciferase (pGL3-Promoter,
Promega), and 50 mmol/L of pre-miR-10a or negative
precursor-miR vector. Renilla luciferase activity was measured
48 h after transfection using Dual Luciferase System (Promega)
in a Berthold Luminometer (Lumat LB 9507) as previously
described (51).
Western Blot Analysis
Proteins extracted from the CML cell line KU812
nucleofected with USF2 siRNA and Silencer Negative
Control-1 were analyzed by Western blot as previously
described (55). The membranes, after being blocked, were
incubated first with primary antibody for USF2 (diluted
1:1,000 for 2 h; Santa Cruz Biotechnology) or h-actin
(1:4,000 for 1 h; Sigma) and then with alkaline phospha-
tase–conjugated secondary antibodies (1:10,000 for 1 h;
Sigma). Bound antibodies were revealed by a chemilumines-
cent reagent (Tropix) and detected using Hyperfilm enhanced
chemiluminescence (Amershan Biosciences). h-Actin was used
as a loading control.
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